Sorry. One more. Anyone is free to tell me how it's wrong.
Me:
ok. everyone is just thinking we dont get trial credit once those patients leave for resection. what trial metrics beyond orr will they apply to
Ai
The belief that the trial "loses credit" for patients who transition to surgical resection is completely incorrect. It is based on a fundamental misunderstanding of clinical trial statistics.
While these patients exit standard tumor-measurement tracking (meaning they no longer contribute to the centralized BICR Objective Response Rate numbers), they continue to count as massive, high-value data points across almost every other primary and secondary endpoint of the study.
These surgical resection patients apply directly to the following key clinical trial metrics:
1. Overall Survival (OS) — The Primary Regulatory Metric
• How it applies: As a binary endpoint (time from first dose to death), every single day these resected, No Evidence of Disease (NED) patients remain alive directly extends the trial's survival curve.
• The Statistical Credit: They are never removed from this metric. They act as an un-evadable statistical anchor that pulls the median OS well past the historical flatlines of standard therapy alone.
2. Clinical Benefit Rate (CBR) or Disease Control Rate (DCR)
• How it applies: This metric combines Complete Responses (CR), Partial Responses (PR), and Stable Disease (SD) maintained for a pre-specified window (typically 8 to 24 weeks).
• The Statistical Credit: Because these patients achieved profound structural regressions or long-term stability prior to their surgical referral, they are locked into the database as a successful clinical benefit hit before they ever enter the operating room.
3. Progression-Free Survival (PFS) via Censoring
• How it applies: PFS tracks the time from the first dose until the tumor grows or the patient dies. When a patient undergoes a successful curative resection, their tumor hasn't grown—it has been physically removed.
• The Statistical Credit: Under standard regulatory protocols, these patients are "censored" at the date of their surgery, or tracked as progression-free as long as they show no signs of disease recurrence. This prevents them from counting as a negative event and directly supports a highly favorable PFS curve.
4. Duration of Response (DoR)
• How it applies: This measures the time from a patient's initial recorded tumor shrinkage until the disease progresses again.
• The Statistical Credit: For resected patients who achieve NED status, the duration of that response is dramatically extended because the macro-tumor burden was eliminated. This creates an outlier data point that extends the overall median duration of response for the entire trial.
The trial captures the entire patient journey from the moment of the first dose. Converting a terminal patient into a clean surgical resection is the ultimate clinical validation, and the statistical framework credits the drug for that survival path".
Me:
ok. everyone is just thinking we dont get trial credit once those patients leave for resection. what trial metrics beyond orr will they apply to
Ai
The belief that the trial "loses credit" for patients who transition to surgical resection is completely incorrect. It is based on a fundamental misunderstanding of clinical trial statistics.
While these patients exit standard tumor-measurement tracking (meaning they no longer contribute to the centralized BICR Objective Response Rate numbers), they continue to count as massive, high-value data points across almost every other primary and secondary endpoint of the study.
These surgical resection patients apply directly to the following key clinical trial metrics:
1. Overall Survival (OS) — The Primary Regulatory Metric
• How it applies: As a binary endpoint (time from first dose to death), every single day these resected, No Evidence of Disease (NED) patients remain alive directly extends the trial's survival curve.
• The Statistical Credit: They are never removed from this metric. They act as an un-evadable statistical anchor that pulls the median OS well past the historical flatlines of standard therapy alone.
2. Clinical Benefit Rate (CBR) or Disease Control Rate (DCR)
• How it applies: This metric combines Complete Responses (CR), Partial Responses (PR), and Stable Disease (SD) maintained for a pre-specified window (typically 8 to 24 weeks).
• The Statistical Credit: Because these patients achieved profound structural regressions or long-term stability prior to their surgical referral, they are locked into the database as a successful clinical benefit hit before they ever enter the operating room.
3. Progression-Free Survival (PFS) via Censoring
• How it applies: PFS tracks the time from the first dose until the tumor grows or the patient dies. When a patient undergoes a successful curative resection, their tumor hasn't grown—it has been physically removed.
• The Statistical Credit: Under standard regulatory protocols, these patients are "censored" at the date of their surgery, or tracked as progression-free as long as they show no signs of disease recurrence. This prevents them from counting as a negative event and directly supports a highly favorable PFS curve.
4. Duration of Response (DoR)
• How it applies: This measures the time from a patient's initial recorded tumor shrinkage until the disease progresses again.
• The Statistical Credit: For resected patients who achieve NED status, the duration of that response is dramatically extended because the macro-tumor burden was eliminated. This creates an outlier data point that extends the overall median duration of response for the entire trial.
The trial captures the entire patient journey from the moment of the first dose. Converting a terminal patient into a clean surgical resection is the ultimate clinical validation, and the statistical framework credits the drug for that survival path".
2
